Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading global provider of 
bio-pharmaceutical contract development and manufacturing provided an update on 
several of its capital projects currently underway in both the United States 
and Belgium.  These projects total over $100 Million and will further expand 
Aji Bio-Pharma's offerings and capabilities globally.  In addition to the 
previously announced highly potent product conjugation and fully isolated fill 
line which has recently commenced operations in its new state of the art 
facility in San Diego, Aji Bio-Pharma is also adding a new fully isolated, 
nested flexible fill line, installing automated packaging and labeling 
equipment, and upgrading its continuous flow and small molecule API 
manufacturing capabilities.  Additional details are below:

    - The Optima 7000 fill line and upgraded aseptic fill suite have been 
      released for client aseptic filling operations (2ml to 100 ml vials). 
    - The HPP/ADC fill line (Isolator system) is scheduled to complete its 
      validation activities, and be released for GMP use during the first half 
      of 2019. 
    - A nested flexible fill line will support a broad range of drug substance 
      APIs, increasing capacity by 50%, enabling larger batch size and a 
      broader range of aseptic filling volumes for vials, syringes and 
      cartridges. 
    - The addition of the automated packaging and labeling equipment offers 
      serialization and aggregation capabilities to support and comply with 
      Drug Supply Chain Security Act. 
    - Terminal Sterilization services are now offered for drug product 
      manufacturing projects requiring this step. 
    - Continuous flow and capability upgrades provide additional capacity and 
      resources to support increased requests for small molecule API 
      manufacturing. 
    - A new Quality Control lab in Belgium will expand operational capabilities 
      and supports growing demand from our clients. 
    - Reconfiguration of GMP manufacturing suites in Belgium to support 
      increased HPAPI capacity and improve process safety with additional 
      instrumentation.

Logo - https://mma.prnewswire.com/media/751177/Aji_BioPharma_Logo.jpg

"These investments not only increase our capabilities and capacities at our US 
and Belgium facilities, they represent a strong step towards achieving our 
Vision Statement of being a leading, trusted, innovative partner to our 
customers and to our people.  In doing so, we can further contribute to what's 
really important to us as a company, that is, improving and extending the lives 
of patients with the drugs we produce," said David Enloe, President and CEO of 
Ajinomoto Bio-Pharma Services. "These capacity expansions ensure that we have 
the assets and capabilities to meet current and future industry needs.  They 
also ensure we continue to attract the best talent to add to our world class 
teams."

About Ajinomoto Bio-Pharma Services
Ajinomoto Bio-Pharma Services is a fully integrated contract development and 
manufacturing organization with sites in Belgium, United States, Japan, and 
India providing comprehensive development, cGMP manufacturing, and aseptic fill 
finish services for small and large molecule APIs and intermediates. Ajinomoto 
Bio-Pharma Services offers a broad range of innovative platforms and 
capabilities for pre-clinical and pilot programs to commercial quantities, 
including: Corynex(R) protein expression technology, oligonucleotide synthesis, 
antibody drug conjugations (ADC), high potency APIs (HPAPI), biocatalysis, 
continuous flow manufacturing and more. Ajinomoto Bio-Pharma Services is 
dedicated to providing a high level of quality and service to meet our client's 
needs. Learn more: www.AjiBio-Pharma.com
 
SOURCE: Ajinomoto Bio-Pharma Services

CONTACT: info@US.AjiBio-Pharma.com